Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.

MLA

De Castro, J., et al. “Phase II Study of a Fixed Dose-Rate Infusion of Gemcitabine Associated with Docetaxel in Advanced Non-Small-Cell Lung Carcinoma.” Cancer Chemotherapy and Pharmacology, vol. 55, no. 2, Feb. 2005, pp. 197–202. EBSCOhost, https://doi.org/10.1007/s00280-004-0869-z.

APA

De Castro, J., Lorenzo, A., Morales, S., Belón, J., Dorta, J., Lizón, J., Madroñal, C., Gallurt, P. M., Casado, E., Feliu, J., & Barón, M. G. (2005). Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemotherapy and Pharmacology, 55(2), 197–202. https://doi.org/10.1007/s00280-004-0869-z

Chicago

De Castro, J, A Lorenzo, S Morales, J Belón, J Dorta, J Lizón, C Madroñal, et al. 2005. “Phase II Study of a Fixed Dose-Rate Infusion of Gemcitabine Associated with Docetaxel in Advanced Non-Small-Cell Lung Carcinoma.” Cancer Chemotherapy and Pharmacology 55 (2): 197–202. doi:10.1007/s00280-004-0869-z.